Source: http://www.google.com/patents/US7763635?dq=3657699
Timestamp: 2015-01-29 06:49:34
Document Index: 272156439

Matched Legal Cases: ['Application No. 2', 'Application No. 2', 'Application No. 04', 'Application No. 2', 'Application No. 04', 'Application No. 2', 'Application No. 04']

Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2095282Mar 15, 1935Oct 12, 1937Standard Oil CoCapillary viscometerUS2956926Sep 23, 1958Oct 18, 1960American Cyanamid CoCoated citric acid particlesUS3065143Apr 19, 1960Nov 20, 1962Richardson Merrell IncSustained release tabletUS4259314Dec 10, 1979Mar 31, 1981Hans LoweyMethod and composition for the preparation of controlled long-acting pharmaceuticalsUS4556552Sep 19, 1983Dec 3, 1985Colorcon, Inc.Enteric film-coating compositionsUS4650664Sep 3, 1985Mar 17, 1987Dr. Karl Thomae GmbhOral mopidamol preparationUS4668684Feb 21, 1986May 26, 1987Degussa AktiengesellschaftCombination of flupirtin and anticholinergic acting spasmolyticUS4713243Jun 16, 1986Dec 15, 1987Johnson & Johnson Products, Inc.Bioadhesive extruded film for intra-oral drug delivery and processUS4828836May 19, 1987May 9, 1989Euroceltique S.A.Controlled release pharmaceutical compositionUS4871548Apr 17, 1987Oct 3, 1989Alza CorporationControlled release dosage form comprising different cellulose ethersUS4940588Mar 17, 1988Jul 10, 1990Elan CorporationControlled release powder and process for its preparationUS5158777Aug 16, 1991Oct 27, 1992E. R. Squibb & Sons, Inc.Captopril formulation providing increased duration of activityUS5203203Oct 10, 1990Apr 20, 1993Bryan William LViscometer for in situ monitoringUS5242927Jul 18, 1988Sep 7, 1993Merck Sharp & Dohme LimitedProdrugs for oxadiazole muscarinic agonistsUS5273760Dec 24, 1991Dec 28, 1993Euroceltigue, S.A.Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS5279660Jun 5, 1992Jan 18, 1994Berol Nobel Stenungsund AbMixture of nonionic cellulose ether and ionic micelle-forming surfactantUS5330766Jan 21, 1993Jul 19, 1994F. H. Faulding & Co. LimitedWater soluble active ingredient core coated with matrix and enteric polymers; high speed, uniform releaseUS5399359Mar 4, 1994Mar 21, 1995Edward Mendell Co., Inc.Controlled release oxybutynin formulationsUS5405648May 10, 1993Apr 11, 1995Hermann; Paul F.Mixing particles with water containing wetting agent, adding liquid polymeric silane coupling agent, agitation while adding liquid urethane prepolymer to coat the particlesUS5455047Jun 15, 1994Oct 3, 1995Bristol-Myers Squibb CompanyDirect compression cholestyramine tablet and solvent-free coating thereforUS5520932Aug 3, 1994May 28, 1996The Upjohn CompanyFine-milled colestipol hydrochlorideUS5582838Dec 22, 1994Dec 10, 1996Merck & Co., Inc.Controlled release drug suspension delivery deviceUS5656286Jan 7, 1994Aug 12, 1997Noven Pharmaceuticals, Inc.Solubility parameter based drug delivery system and method for altering drug saturation concentrationUS5686094Apr 1, 1991Nov 11, 1997Theratech, Inc.Calcium polycarbophilUS5837285Feb 17, 1993Nov 17, 1998Nakamichi; KouichiCompressed, shaped; xylitol and lactose or mannitol; infants, elderly; stability; chemical resistanceUS5912013Apr 21, 1995Jun 15, 1999Shire Laboratories, Inc.Drug deliveryUS5959196Jul 25, 1997Sep 28, 1999Norcross CorporationIn-line viscometerUS5962024Mar 20, 1996Oct 5, 1999Orion-Yhtyma OyPeroral composition for controlled release in the lower gastrointestinal tractUS5972389Sep 19, 1996Oct 26, 1999Depomed, Inc.Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matterUS5998430Nov 17, 1997Dec 7, 1999Dr. R. Pfleger Chemische Fabrik GmbhBladder and urinary system disordersUS6004582May 29, 1998Dec 21, 1999Laboratorios Phoenix U.S.A, Inc.For immediate delivery of a first active agent followed by a monitored, continuous, controlled and/or retarded delivery of a second active agent which is the same or different as the first active agent; time-release agentsUS6024976Aug 11, 1997Feb 15, 2000Noven Pharmaceuticals, Inc.Solubility parameter based drug delivery system and method for altering drug saturation concentrationUS6063808Jun 27, 1997May 16, 2000Sepracor Inc.Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolateUS6141625Jun 4, 1998Oct 31, 2000Dickey-John CorporationViscometer module with crystal resonator-type sensorUS6156340Mar 29, 1996Dec 5, 2000Duquesne University Of The Holy GhostOrally administrable time release drug containing productsUS6197331Jul 24, 1997Mar 6, 2001Perio Products Ltd.Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavityUS6267990Dec 13, 1999Jul 31, 2001Hexal AgPreparation comprising initial dose of ace inhibitor optionally including excipient, first delayed-release pellet, in which active ingredient and optional excipient are covered with coating, second coated delayed-release pelletUS6312726Aug 18, 1994Nov 6, 2001Nippon Shinyaku Co., Ltd.Acid resistant molding for sustained release drugUS6337091Oct 27, 1997Jan 8, 2002Temple University - Of The Commonwealth System Of Higher EducationTo maximally release its drug content in a controlled manner over a long time period while achieving complete dissolutionUS6350471May 31, 2000Feb 26, 2002Pharma Pass LlcTablet comprising core consisting of selected active ingredient and conventional excipients, and coating consisting of water-insoluble, water-permeable film-forming polymer, water-soluble polymer and plasticizerUS6375985Mar 8, 1999Apr 23, 2002Sri InternationalSystem and method for producing drug-loaded microparticlesUS6437000Aug 30, 2000Aug 20, 2002Norstrum Pharmaceuticals, Inc.Controlled release oral dosage for suitable for oral administrationUS6534091Jun 23, 2000Mar 18, 2003Cognis Iberia S. L.MicrocapsulesUS6569462May 21, 1999May 27, 2003Eurand International S.P.A.Spraying tablet with dry particles of drug and/or excipient, electrostatic attraction occurs between them; coating with polymeric membranes having controlled release, gastroresistance, targeted release or taste masking propertiesUS6632451Jun 4, 1999Oct 14, 2003Dexcel Pharma Technologies Ltd.Therapy of disease by the release of drugs in the gastrointestinal tract in a location-and time-dependent mannerUS6635680Jun 10, 2002Oct 21, 2003Nostrum Pharmaceuticals, Inc.Controlled release pellet formulationUS6638528Mar 1, 2002Oct 28, 2003Noven Pharmaceuticals, Inc.Compositions and methods to effect the release profile in the transdermal administration of active agentsUS6645528Oct 23, 2000Nov 11, 2003Acusphere, Inc.Rate of dissolution of drugs can be enhanced by making the drug into a porous matrix formUS6652837Sep 13, 1999Nov 25, 2003Massachusetts Institute Of TechnologyPreparation of novel particles for inhalationUS6682759Feb 1, 2002Jan 27, 2004Depomed, Inc.Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugsUS6772801May 14, 2003Aug 10, 2004Shire Laboratories, Inc.Fluidization of particles for encapsulation in oral dosage pharmaceutical productsUS6897205Mar 9, 2001May 24, 2005Roehm Gmbh & Co. KgMulti-particulate form of medicament, comprising at least two differently coated forms of pelletUS6905709Nov 12, 2001Jun 14, 2005Purdue Pharma, LpStabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS6923988May 1, 2003Aug 2, 2005Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositionsUS6962717Jan 29, 1999Nov 8, 2005Disphar International B.V.Pharmaceutical compositionsUS6974820Oct 2, 2003Dec 13, 2005Bridge Pharma, Inc.Methods for treating urinary incontinence and other disorders using trospiumUS7220430 *Jan 26, 2001May 22, 2007Tanabe Seiyaku Co., Ltd.Sustained-release preparation and process for producing the sameUS20020031550Sep 19, 2001Mar 14, 2002Smithkline Beecham Corporation And Smithkline Beecham P.L.C.Nervous system disorders; Alzheimer's diseaseUS20020047058Aug 29, 2001Apr 25, 2002Frank VerhoffAt least one composition of media bodies provides fragments of milling media bodies that are retained with the milled solid substrate particles in the form of a synergetic commixture produced in the milling process.US20020091099May 24, 1999Jul 11, 2002Brent K. BlackburnOrally active a1 adenosine receptor agonistsUS20020110593Jun 4, 1999Aug 15, 2002Adel PenhasiTherapy of disease by the release of drugs in the gastrointestinal tract in a location- and time-dependent mannerUS20030012815Jan 26, 2001Jan 16, 2003Takashi IshibashiSustained-release preparation and process for producing the sameUS20030054032Nov 12, 2001Mar 20, 2003Benjamin OshlackStabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS20030054041Apr 13, 2001Mar 20, 2003Lemmens Jacobus M.Modified release formulations containing a hypnotic agentUS20030064108Oct 22, 1998Apr 3, 2003Stefan LukasTaste masked pharmaceutical compositionsUS20030158176Oct 25, 2002Aug 21, 2003Ivan RichardsQuaternary ammonium compoundsUS20030185882Nov 6, 2001Oct 2, 2003Vergez Juan A.Pharmaceutical compositions containing oxybutyninUS20030199480Apr 12, 2002Oct 23, 2003David HayesModified release preparationUS20040028729Apr 29, 2003Feb 12, 2004Shojaei Amir H.Releasing into stomach; cone shapes of active materials in matrix; rolling compactionUS20040086571Mar 17, 2003May 6, 2004Skyepharma Canada Inc.For therapy of dyslipidemia and dyslipoproteinemiaUS20040091543Nov 4, 2003May 13, 2004Barbara BellEmbolic compositionsUS20040142035Jan 5, 2004Jul 22, 2004Rong-Kun ChangUse of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeuticsUS20040202693Apr 13, 2004Oct 14, 2004Rong-Kun ChangPharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problemUS20040228917Jun 18, 2004Nov 18, 2004Purdue Pharma LpStabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymerUS20050009862Apr 26, 2004Jan 13, 2005Sabounjian LuannMethod for promoting uninterrupted sleep by administration of trospium chlorideUS20050043342Oct 2, 2003Feb 24, 2005Aberg A.K. GunnarMethods for treating urinary incontinence and other disorders using trospiumUS20060047007Jan 22, 2004Mar 2, 2006Danehower Susan MMethod for treating urinary disordersCA2035155A1Jan 29, 1991Oct 18, 1991Massimo CalanchiPharmaceutical composition for the targeted controlled release of an active principle within the intestine, and particularly within the colonDE1194422BMar 5, 1963Jun 10, 1965Robert Pfleger Chem Fab DrVerfahren zur Herstellung von AzoniaspironortropanderivatenEP1101490A1Jul 26, 1999May 23, 2001Tanabe Seiyaku Co., Ltd.Preparation capable of releasing drug at target site in intestineEP1125586A1Oct 22, 1999Aug 22, 2001Tanabe Seiyaku Co., Ltd.Sustained-release particlesGB1058542A Title not availableWO2000012069A1Aug 26, 1999Mar 9, 2000Pharmacia & Upjohn AbTherapeutic formulation for administering tolterodine with controlled releaseWO2000027364A1Nov 11, 1999May 18, 2000Pharmacia & Upjohn AbNew controlled release bead, a method of producing the same and multiple unit formulation comprising itWO2001015668A1Aug 30, 2000Mar 8, 2001Nostrum Pharmaceuticals IncControlled release pellet formulationWO2001054671A1Jan 26, 2001Aug 2, 2001Kengo IkegamiSustained-release preparation and process for producing the sameWO2001062236A2Jan 23, 2001Aug 30, 2001Deborah JornNew drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agentWO2002060415A1Mar 9, 2001Aug 8, 2002Roehm GmbhMulti-particulate form of medicament, comprising at least two differently coated forms of pelletWO2004000280A1Apr 29, 2003Dec 31, 2003Henry FlannerPharmaceutical formulations with improved bioavailabilityWO2004062577A2Jan 5, 2004Jul 29, 2004Shire Lab IncTwo or more enteric materials to regulate drug releaseWO2004096125A2Apr 13, 2004Nov 11, 2004Rong-Kun ChangPharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem* Cited by examinerNon-Patent CitationsReference1Alloussi, S., et al., "Trospium chloride (Spasmo-lyt�) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, multicentre, placebo-controlled study", Journal of Drug Assessment, 1999, 2: 1-96; Brookwood Medical Publications, pp. 27-39.2Breuel et al., Arzeimittelforschung 43(4): 461-4 (1993).3de Boer, A. G. et al., "Rectal Drug Administration: Clinical Pharmacokinetic considerations", Clinical Pharmacokinetics, 7: 285-311 (1982), ADIS Press Australasia Pty Ltd.4Dmochowski, R.R. et al., "Advancements in Pharmacologic Management of the Overactive Bladder"; Urology 56 (Supplement 6A), Dec. 2000, Elsevier Science, Inc.5EPO Machine Translation of WO 2002/060415.6European Patent Office Supplementary Search Report mailed Jan. 22, 2008 in EP 04 08 0569.7Feely, Intern. J. of Pharm. 44 (1-3): 131-139 (1988).8Friend, Oral Colon-specific Drug Delivery, CRC Press (1992), p. 63.9Froelich et al., Int. J. Clin. Pharmacol. Ther.: 40(7): 295-303 (2002).10Fusgen et al., Int J Clin Pharm Ther, 2000, 38(5), 223-234.11Garely et al., Expert Opinion on Pharmacotherapy, 2002, 3(7), 827-833.12Guo, "Pharmaceutical Applications of naturally occurring water-soluble polymers," Elsevier: Pharmaceutical Science & Technology Today, 1(6): 254-261 (1998).13Hofner et al., World J Urol, 2001, 19, 336-343.14Junemann et al., Neurourology and Urodynamics, 1999, 18(4), 375-376.15Kennon, "Interaction Studies of Cationic Drugs with Anionic Polyelectrolytes-Sodium Carboxymethylcellulose," J. of Pharmaceutical Science 45 (3): 157-160 (1956).16Langguth P., et al., "Intestinal Absorption of the Quarternary Trospium Chloride: Permeability-Lowering factors and Bioavailabilities for Oral Dosage Forms"; European Journal of Pharmeaceutics and Biopharmaceutics, EL Sevier Science Publisher B.V., Amsterdam, NL, vol. 43, No. 3 Jun. 1997, pp. 264-272.17Lapidus, J. of Pharma. Sci. 57(8): 1292-1301 (1968).18Leopold, Drug Targeting Organ Specific Strategies, Ch. 6, pp. 157-170 (2001).19Merck Index, 12th ed. pp. 397, 766, 1341, 1342, & 1667 (1996).20Nugent et al., Gut 48:571-577 (2001).21Office Action of Apr. 14, 2009, in U.S. Appl. No. 10/822,949.22Office Action of Aug. 1, 2008, in U.S. Appl. No. 10/822,949.23Office Action of Aug. 11, 2009, in Mexican Application No. MX2008/060543.24Office Action of Aug. 14, 2009, in U.S. Appl. No. 10/822,949.25Office Action of Dec. 17, 2007, in U.S. Appl. No. 10/980,819.26Office Action of Dec. 2, 2008, in U.S. Appl. No. 10/980,820.27Office Action of Dec. 29, 2009, in U.S. Appl. No. 10/980,819.28Office Action of Feb. 3, 2009, in Canadian Patent Application No. 2,537,103.29Office Action of Feb. 8, 2008, in U.S. Appl. No. 10/822,949.30Office Action of Jan. 13, 2009, in Mexican Application No. MX2008/060543.31Office Action of Jan. 26, 2010, in U.S. Appl. No. 10/980,820.32Office Action of Jan. 4, 2007, in U.S. Appl. No. 10/980,819.33Office Action of Jul. 14, 2008, in Mexican Application No. MX2008/060543.34Office Action of Jul. 8, 2008, in Canadian Patent Application No. 2,537,103.35Office Action of Jun. 18, 2007, in U.S. Appl. No. 10/425,268.36Office Action of Jun. 22, 2007, in U.S. Appl. No. 10/980,819.37Office Action of Jun. 25, 2009, in U.S. Appl. No. 10/980,820.38Office Action of Jun. 27, 2006, in U.S. Appl. No. 10/425,268.39Office Action of Mar. 11, 2009, in European Patent Application No. 04 800 569.802123.40Office Action of May 15, 2009, in U.S. Appl. No. 10/980,819.41Office Action of May 19, 2009, in Canadian Patent Application No. 2,537,103.42Office Action of May 30, 2008, in U.S. Appl. No. 10/980,820.43Office Action of Oct. 13, 2009, in U.S. Appl. No. 10/980,820.44Office Action of Oct. 15, 2008, in European Patent Application No. 04 800 569.802123.45Office Action of Oct. 22, 2007, in Canadian Patent Application No. 2,537,103.46Office Action of Oct. 3, 2008, in U.S. Appl. No. 10/980,819.47Paddock Para IV ANDA Notice letter to Allergan and Supermus Apr. 26, 2010.48Paragraph IV Certification (redacted)-Watson-USP 7,410,978.49Paragraph IV Certification (redacted)�Watson�USP 7,410,978.50Physicians' Desk Reference 55 Edition 2001, 2600-2602.51Physicians' Desk Reference 56 Edition 2002, 2801-2803.52Reitz et al., European Urology, 2004, 45, 510-515.53Remington, 19th Edition, "Sustained Release Drug Delivery Systems" (Chapter 94) pp. 1660-1675, Mack Publishing Co., Easton, PA (1995).54Rodriguez et al., J. Controlled Release 55:67-77 (1998).55Schr�der S, Jetter A, Zaigler M, Weyhenmeyer R, Krumbiegel G, W�chter W, Fuhr U, entitled "Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration," International Journal of Clinical Pharmacology and Therapeutics, vol. 42, No. 10 (2004), pp. 543-549.56Schr�der S, Jetter A, Zaigler M, Weyhenmeyer R, Krumbiegel G, W�chter W, Fuhr U, entitled "Trospium Chloride Absorption From the Human Gastrointestinal Tract Assessed by Local Enteral Adminstration," Eur. J. Clin. Pharmacol. (2002) 58, S97 (Poster demonstaration 4th Annual Congr,. On Clin. Pharmacol. Wiesbgasden, Nov. 2002).57Shojaei, "Systemic Drug Delivery via the Buccal Mucosal Route," Pharm. Tech. pp. 70-81 (2001).58Sigma Aldrich, online catalog, Hydroxypropyl methyl cellulose phthalate, Dec. 21, 2006.59Summons to Attend Oral Argument of Nov. 3, 2009, in European Patent Application No. 04 800 569.802123.60van Hoogdalem, E. J., et al., "Pharmacokinetics of Rectal Drug Administration, Part I: General Considerations and Clinical Applications of Centrally Acting Drugs", Clin. Pharmacokinet. 21 (1): 11-26, 1991, Adis International Limited.61Washington et al., Physiological Pharmaceutics: Barriers to Drug Absorption, 2nd ed., CRC Press, 2001, p. 158.62Yamakita Biol. Pharm. Bul., 18 (10) 1409-1416 (1995).Referenced byCiting PatentFiling datePublication dateApplicantTitleUS8298576 *Nov 16, 2007Oct 30, 2012Supernus Pharmaceuticals, Inc.Sustained-release formulations of topiramateUS8298580 *Dec 17, 2010Oct 30, 2012Supernus Pharmaceuticals, Inc.Sustained-release formulations of topiramateUS8663683Aug 27, 2012Mar 4, 2014Supernus Pharmaceuticals, Inc.Sustained-release formulations of topiramateUS20100221352 *May 12, 2010Sep 2, 2010Supernus Pharmaceuticals, Inc.Pharmaceutical composition for the once-a-day oral administration of trospium chlorideUS20100221353 *May 12, 2010Sep 2, 2010Supernus Pharmaceuticals, Inc.Pharmaceutical Composition For Once-A-Day Administration of Trospium ChlorideUS20100221354 *May 12, 2010Sep 2, 2010Supernus Pharmaceuticals, Inc.Pharmaceutical composition for once-a-day oral administration of trospium chlorideUS20100221355 *May 12, 2010Sep 2, 2010Supernus Pharmaceuticals, Inc.Pharmaceutical composition for once-a-day oral administration of trospium chlorideUS20100221356 *May 12, 2010Sep 2, 2010Supernus Pharmaceuticals, Inc.Pharmaceutical composition for once a day administration of trospium chlorideUS20100222375 *May 12, 2010Sep 2, 2010Supernus Pharmaceuticals, Inc.Pharmaceutical Composition Comprising Trospium Chloride for Once-A-Day AdministrationUS20110287099 *Dec 17, 2010Nov 24, 2011Supernus Pharmaceuticals, Inc.Sustained-release formulations of topiramate* Cited by examinerClassifications U.S. Classification514/299, 514/414, 514/279, 514/409, 514/413, 514/278, 424/468, 514/410International ClassificationA61K9/50, A61K9/48, A61K9/28, A61K31/40, A61K9/20, A61K9/22, A61K31/4747, A61K31/44Cooperative ClassificationA61K31/46, A61K9/20, A61K9/2846, A61K9/5047, A61K9/16, A61K9/4808, A61K9/2086, A61K9/1652, A61K9/5078, A61K9/2866, A61K9/5026European ClassificationA61K9/28H6B2, A61K9/20K4, A61K9/48A, A61K31/44, A61K9/50H6B, A61K9/50H6F2B, A61K9/28H6F2, A61K9/50K2Legal EventsDateCodeEventDescriptionJan 27, 2014FPAYFee paymentYear of fee payment: 4May 12, 2008ASAssignmentOwner name: SUPERNUS PHARMACEUTICALS, INC.,MARYLANDFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIDANE, ARGAW;FLANNER, HENRY H.;BHATT, PADMANABH AND OTHERS;SIGNED BETWEEN 20080227 AND 20080317;US-ASSIGNMENT DATABASE UPDATED:20100329;REEL/FRAME:20934/887Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIDANE, ARGAW;FLANNER, HENRY H.;BHATT, PADMANABH AND OTHERS;SIGNED BETWEEN 20080227 AND 20080317;REEL/FRAME:20934/887Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIDANE, ARGAW;FLANNER, HENRY H.;BHATT, PADMANABH;AND OTHERS;SIGNING DATES FROM 20080227 TO 20080317;REEL/FRAME:020934/0887Owner name: SUPERNUS PHARMACEUTICALS, INC., MARYLANDRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services